The global Neurostimulation Devices Market will be worth USD 13.70 Billion by 2027, according to a current analysis by Emergen Research. The growth of this market can be attributed to the increasing prevalence of chronic nervous disorders. The rising demand for minimally invasive surgeries due to the growing preference among patients and doctors for faster recovery and shorter hospital stays is expected to drive the growth of neurostimulation devices. The increasing prevalence of neurological disorders, such as epilepsy, Dystonia, Parkinson's diseases, is most likely to drive the demand for neurostimulation devices. Technological advancement in the healthcare infrastructure of several countries through the implementation of intelligent technologies is expected to boost the demand for the devices. Implementation of advanced technologies such as Artificial intelligence and machine learning is helping in the development of smart neuromodulation, which is most likely to benefit the patients suffering from brain damage.

The latest market intelligence study on the Neurostimulation Devices market brings in the best of both qualitative and quantitative assessment techniques to explore the market size, share, and status of the Neurostimulation Devices market for the forecast period, 2020 - 2027. The extensive examination of the global business environment provides a detailed analysis of the key driving forces and challenges with the aim to give the stakeholders, business owners, and filed marketing executives a competitive advantage over others. The study further probes into prominent challenges, technology advancements, current trends and lucrative avenues often considered as the boosting elements for the XYZ market for the forecast period, 2020 – 2027

Read more@ https://www.emergenresearch.com/industry-report/neurostimulation-de...
Key Highlights From The Report

In 2019, Medtronic launched the Intellis platform for the management of certain types of chronic intractable pain.

The platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow. It can track patients 24/7 and help in monitoring chronic pain.

The spinal cord stimulator segment held the largest market share of 46.2% in 2019. The rising need for treating spinal injuries and neuropathic pain is most likely to increase the demand for the Spinal Cord Stimulators across the globe.

Pain management is forecasted to grow with the fastest CAGR of 14.0%. The increasing incidence of chronic and acute pain disorders among patients suffering from neurological disorders is expected to increase the usage of neurostimulation devices for pain management.

The Asia Pacific region is expected to be the fastest-growing region over the forecast period. The economic development and increasing Healthcare Budgetary Allocation in developing countries is expected to drive the growth of neurostimulation devices in the region.

Key participants include BOSTON SCIENTIFIC CORPORATION, ST. JUDE MEDICAL, MEDTRONIC, NEURONETICS, INC., Codman & Shurtleff, Inc., NEVRO CORPORATION, INTRAPACE, Abbott Laboratories, LivaNova PLC, and Bayer AG, among others.

Request For Free Sample@ https://www.emergenresearch.com/request-sample/349